Form 4: Director William Pao Receives Immunocore Option Grant

Director William Pao was granted 27,492 stock options in Immunocore Holdings plc with an exercise price of $28.52.

Summary

• Director William Pao received an equity grant of 27,492 share options.
• The options have an exercise price of $28.52 per share.
• The grant date for the transaction was May 27, 2026.
• The options are set to expire on May 26, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Immunocore shares exceeding the $28.52 exercise price.

Future Outlook

The options vest on the earlier of May 27, 2027, or the day prior to the next annual general meeting, contingent on continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized toward long-term clinical and commercial success.

Comparison to Industry Standards

• The use of time-based vesting for director options is consistent with standard compensation practices for mid-cap biotechnology firms.
• The 10-year expiration term is standard for executive and director equity incentive plans.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact upon future exercise of options.

Next Steps

• Vesting of options on May 27, 2027, or the day prior to the next annual general meeting.

Key Dates

Keywords

Immunocore, IMCR, Director Compensation, Stock Options, Insider Transaction